Working… Menu

Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19) (CORON-ACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04335071
Recruitment Status : Terminated (1.) Not possible to recruit the planned number of patients during the planned study period; 2.) "Dexamethason" was included in the standard of care for the study population during the course of the study and inclusion criteria could no longer be met.)
First Posted : April 6, 2020
Last Update Posted : October 14, 2020
Roche Pharma AG
Information provided by (Responsible Party):
University Hospital Inselspital, Berne

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : September 27, 2020
Actual Study Completion Date : September 27, 2020